Characteristics of recipients of p160 v-abl-transduced bone marrow
| Mouse* . | Latency† . | Diagnosis‡ . | PB WBC/ differential2-153 . | Spleen Wt (g) . | Clinicopathologic features2-155 . | Clonality by Southern blot2-154 . |
|---|---|---|---|---|---|---|
| 1 | 35 | B-ALL + mast | 3000# 50% neutrophils | 0.19 | Enlarged LNs, liver, spleen mast cell infiltration, BM replaced with lymphoblasts and mast cells, hindlimb paralysis | Biclonal (LN), 7 clones (spleen)2-160 |
| 2 | 40 | B-ALL | ND | 0.18 | Enlarged LNs | 3 clones (LN, spleen) |
| 3 | 41 | B-ALL | ND | ND | Enlarged LNs | ND |
| 4 | 50 | B-ALL + mast | 2200 80% lymphoblasts | 0.43 | Enlarged LNs, liver, spleen mast cell tumors | 3 clones (LN), 6 clones (liver) |
| 5 | 53 | B-ALL | 16 300 90% lymphoblasts | 0.25 | Enlarged LNs, bloody pleural effusion (B220+) | Biclonal (LN, effusion) |
| 6 | 54 | B-ALL + mast + ma | 5400 90% lymphoblasts | 0.44 | nl LN size but disrupted follicles, liver mast cell and ma tumors, BM replaced with mast/ma cells | Biclonal (spleen) |
| 7 | 62 | B-ALL + mast | 10 000 | 0.42 | Enlarged LNs, diffuse mast cell infiltration of liver, spleen, lungs | Biclonal (LN), 3 clones (spleen) |
| 8 | 63 | B-ALL + mast | ND | 0.34 | Enlarged LNs, paraspinous mass, extensive liver mast cell tumors | Biclonal (LN), 4 clones (spleen)2-160 |
| 9 | 81 | mast + ma | ND | 0.50 | Normal LNs, extensive liver, spleen mast and ma tumors | 4 clones (spleen) |
| Mouse* . | Latency† . | Diagnosis‡ . | PB WBC/ differential2-153 . | Spleen Wt (g) . | Clinicopathologic features2-155 . | Clonality by Southern blot2-154 . |
|---|---|---|---|---|---|---|
| 1 | 35 | B-ALL + mast | 3000# 50% neutrophils | 0.19 | Enlarged LNs, liver, spleen mast cell infiltration, BM replaced with lymphoblasts and mast cells, hindlimb paralysis | Biclonal (LN), 7 clones (spleen)2-160 |
| 2 | 40 | B-ALL | ND | 0.18 | Enlarged LNs | 3 clones (LN, spleen) |
| 3 | 41 | B-ALL | ND | ND | Enlarged LNs | ND |
| 4 | 50 | B-ALL + mast | 2200 80% lymphoblasts | 0.43 | Enlarged LNs, liver, spleen mast cell tumors | 3 clones (LN), 6 clones (liver) |
| 5 | 53 | B-ALL | 16 300 90% lymphoblasts | 0.25 | Enlarged LNs, bloody pleural effusion (B220+) | Biclonal (LN, effusion) |
| 6 | 54 | B-ALL + mast + ma | 5400 90% lymphoblasts | 0.44 | nl LN size but disrupted follicles, liver mast cell and ma tumors, BM replaced with mast/ma cells | Biclonal (spleen) |
| 7 | 62 | B-ALL + mast | 10 000 | 0.42 | Enlarged LNs, diffuse mast cell infiltration of liver, spleen, lungs | Biclonal (LN), 3 clones (spleen) |
| 8 | 63 | B-ALL + mast | ND | 0.34 | Enlarged LNs, paraspinous mass, extensive liver mast cell tumors | Biclonal (LN), 4 clones (spleen)2-160 |
| 9 | 81 | mast + ma | ND | 0.50 | Normal LNs, extensive liver, spleen mast and ma tumors | 4 clones (spleen) |
One recipient of v-abl-transduced marrow died at 285 days after transplantation without evidence of hematologic malignancy.
Time in days to premorbidity or death after transplantation of transduced bone marrow.
Diagnosis based on histopathology, immunophenotype, and molecular analysis as discussed in the text: B-ALL, B-lymphoid leukemia; mast, tumors of mast cells; ma, macrophage tumors (see text).
Peripheral blood leukocyte count (per μL) and differential; ND, not determined.
Based on gross and microscopic pathology and flow cytometric analysis; LN, lymph node; ma, macrophage; BM, bone marrow.
Analysis of proviral integration pattern by Southern blot.
#Estimated from blood smear.
See Figure 4B.